Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected.
CITATION STYLE
Uslu, U., & June, C. H. (2022). CAR T-cell Therapy Meets Clonal Hematopoiesis. Blood Cancer Discovery, 3(5), 382–384. https://doi.org/10.1158/2643-3230.BCD-22-0067
Mendeley helps you to discover research relevant for your work.